Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients

Expert Opinion on Drug Metabolism & Toxicology
Gil AwadaAhmad Awada

Abstract

Left ventricular dysfunction (LVD) is an infrequent but significant side effect of certain molecular-targeted cancer therapies and may lead to treatment modification and impact on disease prognosis. There may be a role for beta blockers (BB), angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in the prevention of LVD. Areas covered: There are multiple definitions for LVD based on clinical and/or imaging features. Molecular-targeted therapies cause reversible LVD. Therapies with well-reported LVD are inhibitors of human epidermal growth factor 2 (HER2), angiogenesis, Abelson murine leukemia viral oncogene homolog (ABL) and the proteasome. BB, ACEI and ARB seem to have a role in the prevention of LVD associated with anthracyclines. Few trials have investigated the role of BB, ACEI and ARB as primary prevention of LVD in molecular-targeted therapies. Their results are not conclusive but a beneficial role cannot be excluded. Expert opinion: Because of inconclusive data, future interventional studies should not include all treated patients with molecular-targeted therapy, but focus on patients at risk for developing LVD. Another option is to study patients who show early signs of LVD to prevent p...Continue Reading

References

Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
May 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·F J GiordanoN Ferrara
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SeidmanDeborah Keefe
May 2, 2002·Nature Medicine·Steven A CroneKuo-Fee Lee
Oct 3, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Haruhiro TokoIssei Komuro
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jul 13, 2004·The New England Journal of Medicine·Steven E LipshultzStephen E Sallan
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarSomnath Sarkar
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S EwerDaniel J Lenihan
Jan 21, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MartyUNKNOWN Dexrazoxane Study Group
Feb 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria Luisa VeronesePeter J O'Dwyer
Jul 25, 2006·Nature Medicine·Risto KerkeläThomas Force
Dec 13, 2006·Journal of the American College of Cardiology·Nihat KalayAli Ergin
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Jan 29, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael BraveRichard Pazdur
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
Apr 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L TelliS Srinivas
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Sep 26, 2008·Molecular Pharmacology·Brian B HasinoffKimberley A O'Hara
Sep 8, 2009·Acta Oncologica·George S OrphanosAlexandros G Ardavanis
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele BaccaraniUNKNOWN European LeukemiaNet
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heikki JoensuuPirkko-Liisa Kellokumpu-Lehtinen
Jan 15, 2010·The Journal of Clinical Investigation·Vishnu ChintalgattuAarif Y Khakoo
Feb 18, 2009·Clinical and Translational Science·Risto KerkelaThomas Force
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Nov 26, 2010·Apoptosis : an International Journal on Programmed Cell Death·Ilona SchonnDorothee C Dartsch
Jan 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriFabio A B Schutz
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.